Severity of pancreatitis after hospitalisation increased in fewer patients given somatostatin (NS).
There was a trend toward fewer complications, especially local, in the somatostatin group. Mortality in both groups was low. Somatostatin appeared to reduce the local complications of acute pancreatitis. A larger trial is necessary to show its beneficial effect conclusively.
Somatostatin is a hormone which suppresses pancreatic exocrine function in animals and man. The action is direct by suppressing glandular secretion as well as indirect by suppressing the secretion of gastrointestinal hormones."' In acute pancreatitis, there is intraglandular activation of digestive enzymes causing glandular destruction and release of these enzymes into the general circulation giving rise to systemic manifestations of organ failure. Theoretically somatostatin, because it suppresses pancreatic enzyme secretion, should exert a beneficial effect on acute pancreatitis.
In animals, somatostatin has been shown to prevent experimentally induced pancreatitis and to lower the mortality of established pancreatitis. The following parameters of the control and somatostatin groups were compared: (1) the value of the laboratory tests at admission and at two days after admission, (2) the severity of pancreatitis as assessed according to the criteria of Imrie et al9 1" at admission and at two days after admission, (3) the mortality, and (4) the incidence and type of complications. The laboratory tests to be compared were determined by Blamey et all to be of prognostic significance. The modified Imrie's criteria'°was used to assess severity. In this modification, the age factor (age >55) was omitted as felt that this was more appropriate as the average age of our patients was over 55 years. The list of criteria used is shown in Table 1 . Patients having three or more of the poor prognosticating factors were assessed to have severe pancreatitis, while those having two or less factors were assessed to have mild pancreatitis. The Mann-Whitney and the X2 test were used in statistical comparisons.
Results
Seventy one patients were included in the study of which 36 were randomised to the control group and 35 to the somatostatin group. The age and sex of the two groups were similar ( Table 2 ). The cause of pancreatitis in all patients is shown in Table 3 . The incidence of gall stones in the control and somatostatin groups was similar ( Table 2) .
The results of the laboratory tests are shown in Table 4 . Overall, the results of 3-6% of the tests were not available mostly because of handling errors. There was no significant difference in any of the tests in the control and somatostatin groups at the time of hospital admission. White blood cell count, urea and LDH concentrations were significantly lower in the somatostatin group when compared with the control Gall stones (n) 19 18 The list of complications is shown in Table 5 . The incidence of complications was lower in the somatostatin group. Pancreatic phlegmon was defined as Pulmonary oedema, congestion and effusion occur frequently in acute pancreatitis'5 leading to impaired arterial blood oxygenation. No difference was found in the arterial P02 levels after somatostatin administration. This indicated that the pulmonary damage was not improved. The serum SGOT concentrations were not different indicating that the degree of liver impairment, which is also seen in acute pancreatitis, was unchanged with somatostatin treatment.
There was a small but significant decrease in the level of serum urea with somatostatin treatment which may indicate some improvement in renal function.
The serum LDH concentration is a measurement of the amount of tissue destruction and in acute pancreatitis, is indicative of the amount of pancreatic and peripancreatic inflamation and necrosis. The LDH was significantly lower in the somatostatin group when compared with the control group at two days after hospitalisation. We further analysed the change in serum LDH levels occurring in the first two days. Six patients in the control group and nine patients in the somatostatin group had raised LDH at admission. At two days after admission, eight patients in the control group had raised LDH including three who initially had raised concentrations, and five in whom the LDH rose. At two days after admission, five patients in the somatostatin group had raised LDH including four patients who initially had raised concentrations and one in whom the LDH rose. Our interpretation of these findings was that local inflamation and necrosis, especially if it has not already started, was suppressed by somatostatin treatment. The significantly lower WBC in the somatostatin group after treatment can also be explained by the suppression of local reaction.
The incidence of local complications including the formation of pseudocyst, abscess, or pancreatic phlegmon was lower in the somatostatin group. This finding appeared to support our LDH data interpretation. We further analyse the relationship between the rise of serum LDH concentrations after hospitalisation and the development of local pancreatic complications. Altogether 11 patients in the entire study develop local complications (eight in the control group and three in the somatostatin group). Of these, nine patients had, at two days after admission, either a rise in the serum LDH concentrations from being initially normal, or a further rise from an already raised concentration. Of the 61 patients who had no local pancreatic complications, only five registered such a rise. Thus, there was a significant correlation between rise in the serum LDH concentrations after hospitalisation and the development of local pancreatic complications (X2= 31-7 by X2 test). Somatostatin administration appeared to reduce this tendency.
The incidence of upper gastrointestinal haemorrhage was lower in the somatostatin group. The numbers were, however, too small to be significant. Somatostatin effectively inhibits basal and stimulated gastric acid output.'617 This may inhibit stress peptic ulcer or gastritis formation which frequently occurs with severe pancreatitis. 18 19 Prognosticating factors have been used in the prediction of the severity of pancreatitis. The modified Imrei's criteria were used in this study and appeared to reflect the true severity as all three deaths occurred in patients predicted to have severe pancreatitis. The number of patients whose pancreatitis increased in severity in the first two days in the somatostatin group (one patient) was less when compared with the control group (five patients).
Because of the small number of patients, however, the difference was not statistically significant. Somatostatin did not seem to have any effect on the mortality of acute pancreatitis. From the previous analysis, the effect of somatostatin is mainly local. The systemic manifestations of pancreatitis are not influenced. Mortality of acute pancreatitis has been shown to be the result of a combination of three factors: local complications, systemic side effects and exacerbation of pre-existing illnesses.'520 Having a beneficial effect on one factor will not significantly change the mortality especially if the mortality is intrinsically low.
Somatostatin does seem to have a beneficial local effect. The question arises as to how can this be applied in the treatment of pancreatitis. The candidates for somatostatin therapy are those who develop local complications but the best timing is before the onset of these complications. In localities with a high incidence of pancreatic pseudocysts, abscesses or necrosis, somatostatin should be started as soon as possible on all patients. Optimally, somatostatin should only be given to patients prone to develop these complications. At present, we are in the process of reviewing the clinical parameters of patients suffering from acute pancreatitis in order to identify those associated with the development of complications. A further trial with somatostatin will be carried out on patients assessed to have a high risk of developing complications. 
